BCBS Minnesota coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Depends on your plan's benefit

Weight loss must NOT be excluded from coverage under the patient's pharmacy benefit. Applies to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open for weight loss agents on coverage delay.

What you need to qualify

Age 12 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, OSA, CVD, and dyslipidemia)
BMI of 25 or higher for patients of Asian descent
BMI at or above the 95th percentile for age and sex
6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult Weight Management

All of:

Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
Patient is an adult (18 years of age or over)
Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Patient is currently on and will continue weight management regimen
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient's age is within FDA labeling OR there is support for use at patient's age
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

BMI >= 30 kg/m2
BMI >= 25 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
BMI >= 27 kg/m2 with at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, T2DM, OSA, CVD, dyslipidemia)

Pediatric Weight Management (12-17 years)

All of:

Weight loss is NOT excluded from coverage under the patient's pharmacy benefit
Patient is new to therapy, not previously approved by Prime, or attempting a repeat weight loss course
Patient is pediatric (12 to 17 years of age)
Patient has been on a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
Patient experienced weight loss of less than 1 pound per week on weight management regimen prior to any pharmacotherapy
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient's age is within FDA labeling OR there is support for use at patient's age
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Plus any one of:

BMI >= 95th percentile for age and sex
BMI >= 30 kg/m2
BMI >= 85th percentile for age and sex AND at least one severe weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, T2DM, OSA)

Repeat Course of Therapy (prior weight loss agent in past 12 months)

All of:

Patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months
Prescriber anticipates success with repeating therapy with any targeted weight loss agent
All other standard weight management criteria met

Documentation to bring

Documentation of BMI (>= 30 kg/m2, or >= 27 kg/m2 with comorbidity, or >= 25 kg/m2 if South/Southeast/East Asian)
Documentation of 6-month weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Documentation of weight loss less than 1 pound per week on weight management regimen prior to pharmacotherapy
Documentation that weight loss is not excluded from coverage under the patient's pharmacy benefit
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful
For pediatric patients: documentation of age (12-17), BMI percentile for age and sex, and qualifying comorbidities if applicable
For repeat course: documentation of prior targeted weight loss agent use and prescriber attestation of anticipated success

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight and For renewal: patient has achieved and maintained >= 5% weight loss from baseline (prior to initiation of the requested agent), OR patient has received less than 52 weeks of therapy on the maximum-tolerated dose. Pediatric renewal also requires current BMI >= 85th percentile for age and sex. Patient must continue weight management regimen and not combine with another weight loss agent or GLP-1. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Co-administration with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
Co-administration with another GLP-1 receptor agonist
Any FDA labeled contraindications
Weight loss coverage excluded from pharmacy benefit

Policy note: Policy applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies. Weight loss agents on coverage delay apply to FlexRx Closed, FlexRx Open, GenRx Closed, and GenRx Open. For the 6-month lifestyle program, the patient must not have lost >= 1 lb/week (i.e., inadequate response to lifestyle). For renewal: Zepbound weight loss renewal requires either < 52 weeks of therapy on maximum-tolerated dose OR >= 5% weight loss from baseline. Pediatric renewal additionally requires current BMI >= 85th percentile. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy